The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to the much lower value of his stock awards. The maker of blood thinner Plavix, schizophrenia treatment Abilify and ...

Executives at Bristol-Myers Squibb Co. told analysts Thursday at a business briefing that the drugmaker has 60 potential drugs in development, seven in late-stage studies, and plenty of money for dealmaking. "Five potential new medicines could be introduced in the next three years," said Dr. Elliot Sigal, head of research and development. The company said it expects future revenue from ...

Some key experimental drugs in late-stage testing by biopharmaceutical company Bristol-Myers Squibb Co.: _ipilimumuab, for melanoma, the most dangerous type of skin cancer. Data from a late-stage study could be presented at a major cancer meeting in June; the company will soon seek regulatory approval for use in patients ...

Drugmaker Bristol-Myers Squibb Co. said Thursday it expects a profit of at least $1.95 per share in 2013, a crucial period because that's when U.S. generic competition will start wiping out sales of its top-selling medicine, the blood thinner Plavix ...